Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Panel Recommendation For Contrave Could Change Obesity Drug Game

Executive Summary

FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.

You may also be interested in...



Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave

The Contrave "complete response" letter could mean research in the category is sidelined now that all three of the current obesity drug candidates have been rejected.

Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave

Orexigen Therapeutics has a big decision on its hands – how to proceed with its Contrave program – now that FDA wants to see a large cardiovascular outcomes study before the drug can be considered for approval.

Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave

Orexigen Therapeutics has a big decision on its hands – how to proceed with its Contrave program – now that FDA wants to see a large cardiovascular outcomes study before the drug can be considered for approval.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel